Effect of Pravastatin on Malondialdehyde-Modified Low-Density Lipoprotein Levels and Coronary Plaque Regression as Determined by Three-Dimensional Intravascular Ultrasound

Tani, Shigemasa; Watanabe, Ichiro; Anazawa, Takeo; Kawamata, Hirofumi; Tachibana, Eizo; Furukawa, Kazuhiro; Sato, Yuichi; Nagao, Ken; Kanmatsuse, Katsuo; Kushiro, Toshio

doi:10.1016/j.amjcard.2005.05.069

Cited by 59 publications

(33 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, several studies that used 3-dimensional IVUS to evaluate changes in coronary plaques after long-term statin therapy showed decreases in atheroma volume. 12,[20][21][22] Our present results show a continuous reduction in atheroma volume under statin treatment from baseline to week 80 (Figure 6), which suggests that lipid-lowering treatment with statins may be able to regress atherosclerosis in coronary disease patients over time; in other words, a late benefit of statin therapy. In the present study, the time course of plaque color change and that of volumetric change differed.…”

Section: Early and Late Benefit Of Statin Therapymentioning

confidence: 66%

Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy

Hirayama

Saito

Ueda

et al. 2009

Circ J

View full text Add to dashboard Cite

Circ J 2009; 73: 718 -725 here have been many reports that intensive lowering of low-density lipoprotein-cholesterol (LDL-C) with 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase inhibitors (statins) is effective in preventing cardiovascular events. [1][2][3] Although the mechanism by which statins confer cardiovascular benefit is not precisely understood, regression of coronary plaque volume and reduction of plaque vulnerability are presumed to play important roles. Angioscopic observations have shown that the presence of yellow plaque is associated with unstable symptoms, which suggests that as plaques become more yellow in appearance, they also become more prone to rupture. [4][5][6] Editorial p 628Angioscopy is used to assess plaque vulnerability on the basis of its color and the presence of thrombi. 7,8 Angioscopy gives a full-color, 3-dimensional perspective of the intracoronary surface morphology, and reasonably accurate information regarding a specific lesion, if performed by trained technicians. Intravascular ultrasound (IVUS) is an alternative imaging modality that provides real-time tomographic images of blood vessels on a monitor. It generates information on vessel wall structure, atheroma volume, and the echogenicity of plaque, which is amenable to qualitative and quantitative analysis and can be used to evaluate plaque regression. 9 The effects of statins on coronary plaque have been evaluated by angioscopy, as well as IVUS, in patients with hypercholesterolemia. Using angioscopy, Takano et al demonstrated that the grade of yellow color decreased during statin therapy, 10 and Nissen et al 11 and Okazaki et al 12 used IVUS to investigate the effects of statins on atheroma volume. However, because no study has serially monitored the coronary plaques of patients receiving statin therapy using both angioscopy and IVUS, the relationship between changes in plaque color and changes in atheroma volume has not been elucidated. Therefore, we used both imaging modalities concurrently to investigate the qualitative and quantitative changes over time in coronary plaques in patients receiving atorvastatin therapy to reduce LDL-C levels to ≤100 mg/dl. Methods Study PopulationPatients with coronary artery disease (CAD) complicated by hypercholesterolemia, with a fasting LDL-C level (Received August 10, 2008; accepted December 2, 2008; released online February 18, 2009

show abstract

Section: Early and Late Benefit Of Statin Therapymentioning

confidence: 66%

Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy

Hirayama

Saito

Ueda

et al. 2009

Circ J

View full text Add to dashboard Cite

show abstract

“…This dose of pitavastatin still produced a significant reduction of the LDL-C level (33.2% reduction), which was equivalent to that of previous trials with other statins in Japan. [15][16][17][18][19] The PVI was significantly reduced in the pitavastatin group, and there were significant positive correlations between the percent change in PVI and both the follow-up LDL-C level and percent change in LDL-C level. In a recent observational study, von Birgelen et al reported a positive correlation between the mean LDL-C level (the mean between baseline and follow-up LDL-C levels) and the annual change in plaque + media size of the LMCA.…”

Section: Discussionmentioning

confidence: 82%

Impact of Lipid-Lowering Therapy With Pitavastatin, a New HMG-CoA Reductase Inhibitor, on Regression of Coronary Atherosclerotic Plaque A 3-Dimensional Intravascular Ultrasound Study

Takashima

Yasukawa²,

Waseda

et al. 2007

Circ J

View full text Add to dashboard Cite

“…15, 16 Intervention studies using statins in Japanese patients have revealed the HDL-C elevating effect of statins to be related to regression of coronary artery plaque volume. 17, 18 The present study demonstrated that only pitavastatin significantly increased HDL-C, and that the percent change in HDL-C was a predictor for the occurrence of MACE in multivariate analysis, suggesting that a more effective statin in HDL-C elevating would be expected to prevent the recurrence of cardiac events. The results that patients with baseline HDL-C levels of 45 mg/dl or less showed a significant increase in HDL-C and prevention of MACE by pitavastatin treatment compared with the no statin further supports this suggestion.…”

Section: Discussionmentioning

confidence: 85%

Comparison of Preventive Effect on Cardiovascular Events With Different Statins - The CIRCLE Study -

Maruyama

Takada

Nishibori

et al. 2011

Circ J

View full text Add to dashboard Cite

Background: Although statins vary in their effectiveness in lowering low-density lipoprotein cholesterol (LDL-C) and increasing high-density lipoprotein cholesterol (HDL-C) levels, there is little evidence that the degree of these changes can explain cardiac risk reduction in Japan. Our objective was to compare the efficacy of statins on serum lipid levels and to explore the association between those changes and cardiac events in patients after percutaneous coronary intervention (PCI). Methods and Results:The 743 consecutive patients who underwent PCI from 2001 to 2008 were retrospectively investigated. Treatment with either atorvastatin or pitavastatin significantly reduced LDL-C compared with pravastatin or no statin. In contrast, only pitavastatin treatment significantly increased HDL-C (13.4±22.9%, P=0.01 vs. no statin). Each statin significantly prevented major adverse cardiac events (MACE) compared with no statin, and pitavastatin was the most effective of all. Multivariate-adjusted analysis revealed that percent changes of both LDL-C and HDL-C independently predicted the incidence of MACE (hazard ratio [HR]: 1.015; 95% confidence interval [CI]: 1.010-1.020, HR: 0.988; 95%CI: 0.981-0.996, respectively). This relationship was preserved in patients with a baseline HDL-C level ≤45 mg/dl, but not HDL-C level >45 mg/ml. Conclusions:The extent of changes in LDL-C and HDL-C with statin treatment would independently alter the risk of cardiac events in Japanese patients for secondary prevention. Statins with varying lipid-modifying ability might provide differing prognosis in patients after PCI. (Circ J 2011; 75: 1951 - 1959 1952MARUYAMA T et al.and Welfare of Japan, and approved by the ethics committee of the hospital.

show abstract

Effect of Pravastatin on Malondialdehyde-Modified Low-Density Lipoprotein Levels and Coronary Plaque Regression as Determined by Three-Dimensional Intravascular Ultrasound

Cited by 59 publications

References 25 publications

Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy

Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy

Impact of Lipid-Lowering Therapy With Pitavastatin, a New HMG-CoA Reductase Inhibitor, on Regression of Coronary Atherosclerotic Plaque A 3-Dimensional Intravascular Ultrasound Study

Comparison of Preventive Effect on Cardiovascular Events With Different Statins - The CIRCLE Study -

Contact Info

Product

Resources

About